Your browser is no longer supported. Please, upgrade your browser.
Settings
ACHV Achieve Life Sciences, Inc. daily Stock Chart
ACHV [NASD]
Achieve Life Sciences, Inc.
Index- P/E- EPS (ttm)-3.35 Insider Own32.17% Shs Outstand1.40M Perf Week-51.34%
Market Cap4.74M Forward P/E- EPS next Y- Insider Trans- Shs Float0.64M Perf Month-71.34%
Income-10.30M PEG- EPS next Q- Inst Own4.50% Short Float7.11% Perf Quarter-75.49%
Sales- P/S- EPS this Y70.10% Inst Trans28.57% Short Ratio1.26 Perf Half Y-71.81%
Book/sh4.94 P/B0.68 EPS next Y- ROA- Target Price- Perf Year-90.73%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.30 - 62.70 Perf YTD-74.82%
Dividend- P/FCF- EPS past 5Y33.60% ROI- 52W High-94.61% Beta1.90
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low2.49% ATR1.01
Employees13 Current Ratio2.00 Sales Q/Q- Oper. Margin- RSI (14)15.81 Volatility10.87% 13.47%
OptionableNo Debt/Eq0.00 EPS Q/Q79.70% Profit Margin- Rel Volume3.48 Prev Close3.35
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume36.19K Price3.38
Recom3.00 SMA20-57.23% SMA50-68.98% SMA200-77.81% Volume126,049 Change0.96%
Jun-19-18 04:01PM  Achieve Life Sciences, Inc. Announces Closing of a $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option PR Newswire
Jun-15-18 08:30AM  Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering PR Newswire -29.81%
Jun-11-18 05:30AM  Achieve Announces Publication of Cytisine Data for Next-Generation Cytisine Molecules PR Newswire
May-25-18 06:09PM  Should You Be Concerned About Achieve Life Sciences Incs (NASDAQ:ACHV) Shareholders? Simply Wall St.
May-23-18 05:30AM  Achieve Life Sciences, Inc. Announces Reverse Stock Split PR Newswire -9.91%
May-09-18 04:15PM  Achieve Reports Financial Results for First Quarter 2018 PR Newswire
May-07-18 05:30AM  Achieve Announces Patent Granted on Novel Formulation of Cytisine PR Newswire
Mar-06-18 05:30AM  Achieve Life Sciences Announces Cytisine Symposium at the 17th World Conference on Tobacco or Health PR Newswire +7.94%
Mar-01-18 04:30PM  Achieve Announces Recent Highlights and Reports Year-End 2017 Financial Results PR Newswire
Feb-20-18 05:30AM  Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study PR Newswire +6.34%
05:30AM  Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study CNW Group
Feb-13-18 07:00AM  Innovative Cancer Immunotherapy Company, Novelogics Biotechnology, Inc. adds Scott D. Cormack to the Board of Directors to Expand Strategic Growth Plans CNW Group
Feb-02-18 12:30PM  A Day Trader's View On Why Bigger Is (Usually) Better Benzinga -5.30%
Jan-26-18 08:05AM  Achieve Life Sciences Making Progress in the Smoking Cessation Market, Recent Events ACCESSWIRE -5.82%
Jan-24-18 05:30AM  Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories PR Newswire +32.84%
05:30AM  Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories CNW Group
Jan-23-18 06:53PM  What Does Achieve Life Sciences Incs (NASDAQ:ACHV) Ownership Structure Look Like? Simply Wall St.
Jan-02-18 04:59PM  A Look At Achieve Life Sciences Inc (NASDAQ:ACHV) And The Healthcare Sector Simply Wall St. +7.20%
Nov-28-17 05:30AM  Achieve Announces Clinical Trial Supply and Cooperation Agreement with the University of Auckland for the Evaluation of Cytisine Compared to Varenicline for Smoking Cessation PR Newswire
05:30AM  Achieve Announces Clinical Trial Supply and Cooperation Agreement with the University of Auckland for the Evaluation of Cytisine Compared to Varenicline for Smoking Cessation CNW Group
Nov-14-17 05:30AM  Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability of Cytisine in Fed and Fasted Subjects PR Newswire
05:30AM  Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability of Cytisine in Fed and Fasted Subjects CNW Group
Nov-09-17 04:05PM  Achieve Reports Financial Results for Third Quarter 2017 PR Newswire
04:05PM  Achieve Reports Financial Results for Third Quarter 2017 CNW Group
Nov-08-17 05:30AM  Achieve to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017 PR Newswire +5.04%
05:30AM  Achieve to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017 CNW Group
Nov-06-17 08:31AM  Achieve Announces Availability of Company Presentation from the Virtual Investor Conference PR Newswire -13.04%
08:31AM  Achieve Announces Availability of Company Presentation from the Virtual Investor Conference CNW Group
Oct-30-17 10:41AM  Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd PR Newswire -12.56%
10:41AM  Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd CNW Group
08:31AM  Achieve Announces Company Presentation at Virtual Investor Conference on November 2, 2017 PR Newswire
08:31AM  Achieve Announces Company Presentation at Virtual Investor Conference on November 2, 2017 CNW Group
Oct-26-17 05:30AM  Achieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of Cytisine CNW Group +15.34%
Oct-04-17 05:30AM  Achieve Announces Advancement of Cytisine Clinical Development Program PR Newswire
Sep-14-17 04:05PM  Achieve Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC PR Newswire
04:05PM  Achieve Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC CNW Group
Aug-16-17 06:00AM  Achieve Announces Initiation of Cytisine Clinical Development Program CNW Group -5.88%
Aug-10-17 04:30PM  Achieve Announces FDA Acceptance of the Investigational New Drug Application (IND) for Cytisine as a Smoking Cessation Treatment PR Newswire -14.41%
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has a license agreement with Sopharma AD and University of Bristol. The company is headquartered in Bothell, Washington.